Cargando…
Risk of severe COVID-19 in hypertensive patients treated with renin-angiotensin-aldosterone system inhibitors
INTRODUCTION: There is controversy concerning the use of angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II type-I receptor blockers (ARB) for treating hypertensive patients with Covid-19. It has been hypothesized that these drugs might increase the risk of severe Covid-19, but some a...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier España, S.L.U.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7316050/ https://www.ncbi.nlm.nih.gov/pubmed/32651067 http://dx.doi.org/10.1016/j.medcli.2020.06.013 |
_version_ | 1783550371685203968 |
---|---|
author | Golpe, Rafael Pérez-de-Llano, Luis A. Dacal, David Guerrero-Sande, Hector Pombo-Vide, Beatriz Ventura-Valcárcel, Pablo |
author_facet | Golpe, Rafael Pérez-de-Llano, Luis A. Dacal, David Guerrero-Sande, Hector Pombo-Vide, Beatriz Ventura-Valcárcel, Pablo |
author_sort | Golpe, Rafael |
collection | PubMed |
description | INTRODUCTION: There is controversy concerning the use of angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II type-I receptor blockers (ARB) for treating hypertensive patients with Covid-19. It has been hypothesized that these drugs might increase the risk of severe Covid-19, but some authors suggested that blocking the renin-angiotensin system might actually decrease this risk. METHODS: Retrospective cohort study of all the consecutive hypertensive patients with confirmed SARS-CoV-2 infection in a health area. The outcome variable was hospitalization because of severe Covid-19. RESULTS: 539 subjects were diagnosed of SARS-CoV-2 infection. Of these, 157 (29.1%) had hypertension and were included in the study. Sixty-nine cases (43.9%) were hospitalized because of severe Covid-19. In multivariable analysis older age, diabetes and hypertensive myocadiopathy were related to a higher risk of hospital admission. ARB treatment was associated with a significantly lower risk of hospitalization (HR: 0.29, 95% CI: 0.10 – 0.88). A similar albeit not significant trend was observed for ACEI. CONCLUSION: ARB or ACEI treatment was not associated with a worse clinical outcome in consecutive hypertensive patients infected by SARS-CoV-2. |
format | Online Article Text |
id | pubmed-7316050 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Elsevier España, S.L.U. |
record_format | MEDLINE/PubMed |
spelling | pubmed-73160502020-06-25 Risk of severe COVID-19 in hypertensive patients treated with renin-angiotensin-aldosterone system inhibitors Golpe, Rafael Pérez-de-Llano, Luis A. Dacal, David Guerrero-Sande, Hector Pombo-Vide, Beatriz Ventura-Valcárcel, Pablo Med Clin (Barc) Brief Report INTRODUCTION: There is controversy concerning the use of angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II type-I receptor blockers (ARB) for treating hypertensive patients with Covid-19. It has been hypothesized that these drugs might increase the risk of severe Covid-19, but some authors suggested that blocking the renin-angiotensin system might actually decrease this risk. METHODS: Retrospective cohort study of all the consecutive hypertensive patients with confirmed SARS-CoV-2 infection in a health area. The outcome variable was hospitalization because of severe Covid-19. RESULTS: 539 subjects were diagnosed of SARS-CoV-2 infection. Of these, 157 (29.1%) had hypertension and were included in the study. Sixty-nine cases (43.9%) were hospitalized because of severe Covid-19. In multivariable analysis older age, diabetes and hypertensive myocadiopathy were related to a higher risk of hospital admission. ARB treatment was associated with a significantly lower risk of hospitalization (HR: 0.29, 95% CI: 0.10 – 0.88). A similar albeit not significant trend was observed for ACEI. CONCLUSION: ARB or ACEI treatment was not associated with a worse clinical outcome in consecutive hypertensive patients infected by SARS-CoV-2. Elsevier España, S.L.U. 2020-12-11 2020-06-25 /pmc/articles/PMC7316050/ /pubmed/32651067 http://dx.doi.org/10.1016/j.medcli.2020.06.013 Text en © 2020 Elsevier España, S.L.U. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Brief Report Golpe, Rafael Pérez-de-Llano, Luis A. Dacal, David Guerrero-Sande, Hector Pombo-Vide, Beatriz Ventura-Valcárcel, Pablo Risk of severe COVID-19 in hypertensive patients treated with renin-angiotensin-aldosterone system inhibitors |
title | Risk of severe COVID-19 in hypertensive patients treated with renin-angiotensin-aldosterone system inhibitors |
title_full | Risk of severe COVID-19 in hypertensive patients treated with renin-angiotensin-aldosterone system inhibitors |
title_fullStr | Risk of severe COVID-19 in hypertensive patients treated with renin-angiotensin-aldosterone system inhibitors |
title_full_unstemmed | Risk of severe COVID-19 in hypertensive patients treated with renin-angiotensin-aldosterone system inhibitors |
title_short | Risk of severe COVID-19 in hypertensive patients treated with renin-angiotensin-aldosterone system inhibitors |
title_sort | risk of severe covid-19 in hypertensive patients treated with renin-angiotensin-aldosterone system inhibitors |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7316050/ https://www.ncbi.nlm.nih.gov/pubmed/32651067 http://dx.doi.org/10.1016/j.medcli.2020.06.013 |
work_keys_str_mv | AT golperafael riskofseverecovid19inhypertensivepatientstreatedwithreninangiotensinaldosteronesysteminhibitors AT perezdellanoluisa riskofseverecovid19inhypertensivepatientstreatedwithreninangiotensinaldosteronesysteminhibitors AT dacaldavid riskofseverecovid19inhypertensivepatientstreatedwithreninangiotensinaldosteronesysteminhibitors AT guerrerosandehector riskofseverecovid19inhypertensivepatientstreatedwithreninangiotensinaldosteronesysteminhibitors AT pombovidebeatriz riskofseverecovid19inhypertensivepatientstreatedwithreninangiotensinaldosteronesysteminhibitors AT venturavalcarcelpablo riskofseverecovid19inhypertensivepatientstreatedwithreninangiotensinaldosteronesysteminhibitors AT riskofseverecovid19inhypertensivepatientstreatedwithreninangiotensinaldosteronesysteminhibitors |